Clinical trials: Sts
Advanced Soft Tissue Sarcoma
A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in Greece
This non-interventional study aims primarily at assessing the clinical effectiveness and the impact of the therapy on cancer-related symptoms and patients' HRQoL.
- Trial name
- beYOND-STS (NCT02618122)
- Where
- Greece
- Volunteers
- 63 people
- Sponsor
- Genesis Pharma S.A.
Soft Tissue Sarcoma
Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
The study is aimed at evaluating the safety of L19TNF in combination with the most appropriate dose of doxorubicin.
- Trial name
- DOXO75 (NCT04032964)
- Testing
- L19TNF, DOXORUBICIN
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Philogen S.p.A.
Tumors
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).
- Trial name
- NCT02549937
- Testing
- surufatinib
- Where
- 12 sites in United States, Italy
- Volunteers
- 130 people
- Sponsor
- Hutchmed
Metastatic Adult Soft Tissue Sarcoma
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.
The main objective of the trial is to document the preliminary antitumor activity of two doses of NGR-hTNF administered either alone or in combination with doxorubicin in locally advanced or metastatic soft-tissue sarcoma (STS)…
- Trial name
- NCT00484341
- Testing
- low-dose NGR-hTNF, high-dose NGR-hTNF, Doxorubicin
- Where
- 7 sites in France, Italy and 1 more
- Volunteers
- 69 people
- Sponsor
- AGC Biologics S.p.A.
Cancer
A Phase II Study of Anlotinib in STS Patients
Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- ALTN/STS (NCT01878448)
- Testing
- Anlotinib
- Where
- 16 sites in China
- Volunteers
- 166 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Cisplatin-Induced Hearing Loss in Children Who Had Standard-risk Hepatoblastoma
A Compassionate Use Program to Provide Access to Sodium Thiosulfate
This is a CUP which is designed to provide treatment access of STS to pediatric patients for the protection from Cisplatin-Induced Hearing Loss in children who had standard-risk hepatoblastoma.
- Trial name
- NCT04132882
- Testing
- Sodium Thiosulfate (STS)
- Where
- Turkey (Türkiye)
- Sponsor
- TRPHARM